GSK calls for urgent focus on adult vaccination as ageing populations face rising disease burden

As the world’s population ages at an unprecedented pace, global biopharma major GSK is calling for a renewed focus on adult immunisation to prevent avoidable disease, reduce healthcare costs, and protect economic productivity.

Speaking at GSK’s Global Media Days on September 2 at Wavre site in Belgium — one of the world’s largest vaccine manufacturing site, company leaders and public health experts underscored the growing threat of vaccine-preventable diseases such as respiratory syncytial virus (RSV) and shingles, particularly among older adults and immunocompromised populations.

RSV is a common respiratory virus that typically causes mild, cold-like symptoms. However, it can lead to serious lung infections, especially in infants and older adults, whereas Shingles, also known as herpes